Making Cents Sense

ARMOUR Residential REIT has given income investors the number they wanted to see: $0.24 per share for October . That works out to $2.88 per share annually if the payment were maintained for twelve months. At a recent closing price near $14.10, that implies a yield north of 20%. That is the kind of yield that can make an income investor stop scrolling. It is also exactly the kind of yield that makes me stop and ask what the market thinks could go wrong. ARMOUR announced on September 24 that it expects to pay a $0.24 common-stock dividend for October, with an October 15 record date and an October 29 payment date. But the company carefully described the announcement as guidance , and ARMOUR explicitly states that actual dividends remain subject to the discretion of its board. That wording matters. The October announcement tells me that management currently intends to preserve the monthly payout. It does not tell me whether the payout is economically sustainable, whether book value is hold...

I have a confession to make about IPOs: whenever I hear that a fast-growing company is finally coming public, my first reaction is excitement. My second reaction is immediately wondering how much of that excitement Wall Street has already stuffed into the price. Oura is a perfect example. The smart-ring maker is preparing to trade on Nasdaq under the ticker OURA , and on the surface, there is an awful lot for me to like about the business. Revenue is exploding. Membership is growing even faster. The company is profitable. Its brand has become nearly synonymous with the smart-ring category. And, perhaps most importantly, Oura increasingly looks less like a company that sells expensive pieces of wearable hardware and more like a recurring-revenue health platform that happens to begin the customer relationship with a ring. Then I look at the proposed valuation. And my enthusiasm suddenly develops adult supervision. Oura and existing shareholders are offering 50 million shares at an expect...

Ticker: ONON Rating: Buy 12-Month Price Target: $38 Current reference price: approximately $30 On Holding just gave investors something much bigger than another pair of expensive running shoes. At its September 22 investor day, the Swiss sportswear company laid out a plan that effectively asks investors to believe three things at once: On can remain one of the fastest-growing premium athletic brands in the world, it can continue expanding profitability while spending aggressively on growth, and it can return as much as $1 billion to shareholders without starving the business of the capital needed to challenge Nike and Adidas. That is an ambitious combination. It is also becoming increasingly difficult to dismiss. On now expects net sales to reach at least CHF5.6 billion by 2029, accompanied by high-teens annual constant-currency growth, gross margins of at least 65%, and an adjusted EBITDA margin of 22% or better. At the same time, the board has authorized the company's first share...

I tend to approach corporate recovery plans with the same caution I bring to a suspiciously inexpensive home renovation estimate. The finished version looks wonderful. The schedule is reassuring. Somewhere between the attractive rendering and the final invoice, however, reality usually requests a meeting. Charles River Laboratories has given investors an ambitious picture of its business in 2030, and I think the interesting question is what has to happen between here and there. My initial conclusion is that CRL has a credible recovery framework, but the earnings ambition cannot be explained by cutting costs alone. The revenue assumptions do substantial work. At the midpoint of management’s growth target, my simplified model produces roughly 9.4% annual adjusted operating-profit growth. With no revenue growth, the same endpoint margin produces only about 3.2%. That difference is where I would concentrate my research, rather than letting a large savings announcement do all the persuasion...